|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-05
|
$336,565
|
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
5R03CA215940-02
|
$75,288
|
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-03
|
$349,694
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.
|
1R44CA228694-01
|
$300,000
|
|
SILBERSTEIN, DAVID
|
BIOMIMETIX JV, LLC
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
1R01CA211328-01
|
$404,888
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Developing a translational pipeline for NF1-mutant malignancies
|
5U01CA202943-03
|
$235,046
|
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma
|
1R43CA221389-01A1
|
$224,919
|
|
LING, XIANG
|
CANGET BIOTEKPHARMA, LLC
|
|
Determining the Epigenetic Mechanisms Driving Tissue Factor (F3) Upregulation and its Role in Metastatic Osteosarcoma
|
5F31CA213965-02
|
$44,524
|
|
BAYLES, IAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining novel drivers and predictive signatures of metastasis in osteosarcoma th
|
5F30CA186633-05
|
$49,524
|
|
MORROW, JAMES
|
CASE WESTERN RESERVE UNIVERSITY
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
5K08CA179084-05
|
$112,331
|
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion
|
5R01CA189299-04
|
$338,550
|
|
KELLER, CHARLES
|
CHILDREN'S CANCER THERAPY DEVELOP/INST
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$83,611
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,352,827
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
5R01CA207983-02
|
$449,691
|
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-23
|
$214,456
|
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
|
5P01CA217959-02
|
$2,171,238
|
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
An organotypic model recapitulating colon cancer microenvironment and metastasis
|
5U01CA214300-02
|
$673,627
|
|
HUANG, EMINA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer
|
1R44CA224472-01A1
|
$298,791
|
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
|
5U01CA217858-02
|
$1,314,469
|
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer
|
5F31CA192891-05
|
$49,524
|
|
PRICE, JESSICA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of Fusobacterium in colorectal cancer treatment, tumor ecology and chemotherapeutic efficacy
|
1K99CA229984-01
|
$128,963
|
|
BULLMAN, SUSAN
|
DANA-FARBER CANCER INST
|
|
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
|
5K08CA191058-04
|
$177,120
|
|
JESELSOHN, RINATH
|
DANA-FARBER CANCER INST
|
|
Primers: Combining Radiotherapy and Immunotherapy using next genertaion radiotherapy biomaterials
|
5R21CA205094-02
|
$191,669
|
|
NGWA, WILFRED
|
DANA-FARBER CANCER INST
|
|
Targeting intratumor heterogeneity in breast cancer
|
5R35CA197623-04
|
$1,157,073
|
|
POLYAK, KORNELIA
|
DANA-FARBER CANCER INST
|
|
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
|
5P01CA206978-03
|
$1,755,838
|
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
|
5R35CA210057-03
|
$1,007,233
|
|
ZHAO, JEAN
|
DANA-FARBER CANCER INST
|
|
Exploiting the epithelial-to-mesenchymal transition for the differentiation of cancer stem cells
|
4R00CA201574-03
|
$249,000
|
|
PATTABIRAMAN, DIWAKAR
|
DARTMOUTH COLLEGE
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
The Duke Preclinical Research Resources for Quantitative Imaging Biomarkers
|
5U24CA220245-02
|
$631,958
|
|
BADEA, CRISTIAN
|
DUKE UNIVERSITY
|
|
Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer
|
1U01CA217514-01A1
|
$638,270
|
|
SHEN, XILING
|
DUKE UNIVERSITY
|
|
Perfluorocarbon Nanodroplets for the Detection and Treatment of Nodal Metastases
|
5F30CA216939-02
|
$49,524
|
|
YARMOSKA, STEVEN
|
EMORY UNIVERSITY
|
|
Microdevice-Armed Macrophage For Treating Cancer
|
5R03CA202334-02
|
$70,610
|
|
GUAN, JINGJIAO
|
FLORIDA STATE UNIVERSITY
|
|
Overcoming stromal barriers to therapeutics in pancreas cancer
|
5R01CA161112-08
|
$513,402
|
|
HINGORANI, SUNIL
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Late Effects of Treatment in Wilms Tumor Survivors and Offspring
|
3R01CA054498-25S1
|
$44,259
|
$44,259
|
LEISENRING, WENDY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
The Pacific Northwest Prostate Cancer SPORE
|
2P50CA097186-16A1
|
$2,155,387
|
|
NELSON, PETER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Defining and targeting mechanisms of pancreas cancer pathogenesis
|
5R50CA211425-02
|
$139,320
|
|
WHITTLE, MARTIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Validation of a novel, adjuvant implant for post-metastatic skeletal lesions
|
1R43CA221553-01A1
|
$299,958
|
|
MARGULIES, BRYAN
|
FUSOLOGICS, LLC
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-05
|
$303,118
|
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
Investigating the Functional Consequences of SMARCE1 loss in Clear Cell Meningioma
|
1F31CA228441-01
|
$38,080
|
|
ST PIERRE, ROODOLPH
|
HARVARD UNIVERSITY
|
|
The role of Lin28/let 7 pathway in Wilms' tumor
|
5F99CA212487-02
|
$31,994
|
$31,994
|
YERMALOVICH, ALENA
|
HARVARD UNIVERSITY
|
|
Cholesterol promotes breast cancer progression: establishing the mechanisms
|
5K08CA190770-05
|
$168,571
|
|
GALLAGHER, EMILY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Functional interactions between AKT and HSF-1 in breast cancer progression
|
5K22CA207575-02
|
$162,000
|
|
CARPENTER, RICHARD
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
|
2R01CA167291-06
|
$493,726
|
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Nanosystems Biology Cancer Center
|
5U54CA199090-05
|
$2,073,361
|
|
HEATH, JAMES
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
Total relevant funding to Wilm's Tumor for this search: $4,995,401
|